Jong-Ho Park1, Bruce Ovbiagele2. 1. From the Department of Stroke Neurology (J.-H.P.), Myongji Hospital, Goyang, Korea; and the Department of Neurosciences (J.-H.P., B.O.), Medical University of South Carolina, Charleston. 2. From the Department of Stroke Neurology (J.-H.P.), Myongji Hospital, Goyang, Korea; and the Department of Neurosciences (J.-H.P., B.O.), Medical University of South Carolina, Charleston. Ovibes@musc.edu.
Abstract
OBJECTIVE: To investigate the effect of optimal combination of evidence-based drug therapies including antihypertensive agents, lipid modifiers, and antithrombotic agents on risk of recurrent vascular events after stroke. METHODS: We analyzed the database of a multicenter trial involving 3,680 recent noncardioembolic stroke patients aged 35 years or older and followed for 2 years. Patients were categorized by appropriateness level 0 to III depending on the number of drugs prescribed divided by the number of drugs potentially indicated for each patient (0 = none of the indicated medications prescribed and III = all indicated medications prescribed). Independent associations of medication appropriateness level with recurrent stroke (primary outcome), stroke/coronary heart disease/vascular death as major vascular events (secondary outcome), and death (tertiary outcome) were assessed. RESULTS: The unadjusted rate of stroke declined with increasing medication appropriateness level (15.9% for level 0, 10.3% for level I, 8.6% for level II, and 7.3% for level III). Compared with level 0: the adjusted hazard ratio of stroke for level I was 0.51 (95% confidence interval, 0.21-1.25), level II 0.50 (0.23-1.09), and level III 0.39 (0.18-0.84); of stroke/coronary heart disease/vascular death for level I 0.60 (0.32-1.14), level II 0.45 (0.25-0.80), and level III 0.39 (0.22-0.69); and of death for level I 0.89 (0.30-2.64), level II 0.71 (0.26-1.93), and level III 0.35 (0.13-0.96). CONCLUSIONS: Optimal combination of secondary prevention medication classes after a recent noncardioembolic stroke is associated with a significantly lower risk of stroke, major vascular events, and death.
OBJECTIVE: To investigate the effect of optimal combination of evidence-based drug therapies including antihypertensive agents, lipid modifiers, and antithrombotic agents on risk of recurrent vascular events after stroke. METHODS: We analyzed the database of a multicenter trial involving 3,680 recent noncardioembolic strokepatients aged 35 years or older and followed for 2 years. Patients were categorized by appropriateness level 0 to III depending on the number of drugs prescribed divided by the number of drugs potentially indicated for each patient (0 = none of the indicated medications prescribed and III = all indicated medications prescribed). Independent associations of medication appropriateness level with recurrent stroke (primary outcome), stroke/coronary heart disease/vascular death as major vascular events (secondary outcome), and death (tertiary outcome) were assessed. RESULTS: The unadjusted rate of stroke declined with increasing medication appropriateness level (15.9% for level 0, 10.3% for level I, 8.6% for level II, and 7.3% for level III). Compared with level 0: the adjusted hazard ratio of stroke for level I was 0.51 (95% confidence interval, 0.21-1.25), level II 0.50 (0.23-1.09), and level III 0.39 (0.18-0.84); of stroke/coronary heart disease/vascular death for level I 0.60 (0.32-1.14), level II 0.45 (0.25-0.80), and level III 0.39 (0.22-0.69); and of death for level I 0.89 (0.30-2.64), level II 0.71 (0.26-1.93), and level III 0.35 (0.13-0.96). CONCLUSIONS: Optimal combination of secondary prevention medication classes after a recent noncardioembolic stroke is associated with a significantly lower risk of stroke, major vascular events, and death.
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: P Bramlage; C Messer; N Bitterlich; C Pohlmann; A Cuneo; E Stammwitz; J Tebbenjohanns; H Gohlke; J Senges; U Tebbe Journal: Heart Date: 2010-03-29 Impact factor: 5.994
Authors: Keith A A Fox; Omar H Dabbous; Robert J Goldberg; Karen S Pieper; Kim A Eagle; Frans Van de Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Frederick A Anderson; Christopher B Granger Journal: BMJ Date: 2006-10-10
Authors: Andrew T Yan; Raymond T Yan; Mary Tan; Thao Huynh; Kamyar Soghrati; Lawrence J Brunner; Paul DeYoung; David H Fitchett; Anatoly Langer; Shaun G Goodman Journal: Am Heart J Date: 2007-09-14 Impact factor: 4.749
Authors: James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer Journal: JAMA Date: 2004-02-04 Impact factor: 56.272
Authors: Bruce Ovbiagele; Larry B Goldstein; Randall T Higashida; Virginia J Howard; S Claiborne Johnston; Olga A Khavjou; Daniel T Lackland; Judith H Lichtman; Stephanie Mohl; Ralph L Sacco; Jeffrey L Saver; Justin G Trogdon Journal: Stroke Date: 2013-05-22 Impact factor: 7.914
Authors: Tian-Tian Ma; Ian C K Wong; Kenneth K C Man; Yang Chen; Thomas Crake; Muhiddin A Ozkor; Ling-Qing Ding; Zi-Xuan Wang; Lin Zhang; Li Wei Journal: PLoS One Date: 2019-01-18 Impact factor: 3.240
Authors: Tian-Tian Ma; Ian C K Wong; Cate Whittlesea; Kenneth K C Man; Wallis Lau; Zixuan Wang; Ruth Brauer; Thomas M MacDonald; Isla S Mackenzie; Li Wei Journal: BMC Med Date: 2021-02-03 Impact factor: 8.775
Authors: Narayanaswamy Venketasubramanian; Craig Anderson; Hakan Ay; Selma Aybek; Waleed Brinjikji; Gabriel R de Freitas; Oscar H Del Brutto; Klaus Fassbender; Miki Fujimura; Larry B Goldstein; Roman L Haberl; Graeme J Hankey; Wolf-Dieter Heiss; Isabel Lestro Henriques; Carlos S Kase; Jong S Kim; Masatoshi Koga; Yoshihiro Kokubo; Satoshi Kuroda; Kiwon Lee; Tsong-Hai Lee; David S Liebeskind; Gregory Y H Lip; Stephen Meairs; Roman Medvedev; Man Mohan Mehndiratta; Jay P Mohr; Masao Nagayama; Leonardo Pantoni; Panagiotis Papanagiotou; Guillermo Parrilla; Daniele Pastori; Sarah T Pendlebury; Luther Creed Pettigrew; Pushpendra N Renjen; Tatjana Rundek; Ulf Schminke; Yukito Shinohara; Wai Kwong Tang; Kazunori Toyoda; Katja E Wartenberg; Mohammad Wasay; Michael G Hennerici Journal: Cerebrovasc Dis Date: 2021-03-23 Impact factor: 2.762
Authors: Karen C Albright; Virginia J Howard; George Howard; Paul Muntner; Vera Bittner; Monika M Safford; Amelia K Boehme; J David Rhodes; T Mark Beasley; Suzanne E Judd; Leslie A McClure; Nita Limdi; Justin Blackburn Journal: J Am Heart Assoc Date: 2017-08-02 Impact factor: 5.501